Prof. Pierre J. Magistretti, MD, PhD
Scientific Advisor, Co‐founder
Pierre Magistretti is Professor at Ecole Polytechnique Fédérale de Lausanne (EPFL) in the Brain and Mind Institute (BMI), of which he was director for a decade. He is also the Dean of Biological and Environment Science and Engineering at KAUST. Prof. Magistretti is an internationally-recognized neuroscientist who has made significant contributions in the field of brain metabolism and glial cells biology. He is the author of over 250 publications and recipient of numerous awards. Prof. Magistretti co-founded GliaPharm as a spinoff of three decades of research performed in his laboratory at EPFL with the objectives to clinically apply fundamental discoveries he has pioneered. He serves as GliaPharm's Scientific Advisor and Board Member.
Prof. Magistretti is also the president of the International Brain Research Organization (IBRO). He has been member of the Swiss National Science Foundation scientific council, President of the Federation of European Neuroscience Societies (2002-2004) and elected Professor at the International Chair of the Collège de France (2007-2008).
Dr. Charles Finsterwald, PhD
Chief Scientific Officer, Co‐founder
Dr. Charles Finsterwald is a neuroscientist with expertise in molecular, cellular and cognitive neuroscience. He is co-founder of GliaPharm where he serves as Chief Scientific Officer (CSO) and Board Member.
Dr. Finsterwald has been a post-doctoral researcher at New York University (NYU) before joining Prof. Magistretti's laboratory at Ecole Polytechnique Fédérale de Lausanne (EPFL, Switzerland). Dr. Finsterwald holds a BSc and MSc in Biology and Immunology from the University of Lausanne, and a PhD in neuroscience from the Lemanic Neuroscience Doctoral School, Switzerland. He also graduated in Project Management from NYU and has specialized in the management of start-up and biotechnology ventures at EPFL.
Dr. Sylvain Lengacher, PhD
Chief Executive Officer, Co‐founder
Dr. Sylvain Lengacher is a molecular biologist and has over 20 years of experience in the field of neuroscience research, biotechnology management, and technology transfer. He is co-founder of GliaPharm where he serves as Chief Executive Officer (CEO) and Chairman of the Board.
Dr. Lengacher has been a research director at Ecole Polytechnique Fédérale de Lausanne (EPFL, Switzerland) for the past 10 years. He is also the Knowledge and Technology Transfer (KTT) officer responsible for the processing and management of intellectual property of the National Centres of Competence in Research (NCCR) program Synapsy of the Swiss National Science Foundation. Dr. Lengacher holds a PhD in molecular biology and has also graduated from EPFL in the Management of Biotech, Medtech and Pharma Ventures.
Chief Financial Officer, Co‐founder
Mr. Ambroise Magistretti is an entrepreneur in the healthcare sector. He is co-founder of GliaPharm where he serves as Chief Financial Officer (CFO) and Board Member.
Mr. Magistretti is also partner and on the scientific and industrial advisory board of SeveneastHealthcare, a healthcare investment firm. He has founded and managed The Healthcare Biotech Fund, and has experience in asset management and healthcare equity research. Mr. Magistretti also serves as treasurer and Board Member to the Swiss NGO International Foundation for Population Development (IFPD).
Mr. Magistretti holds a BSc in Biochemistry with Honours from University College of London (UCL) and an MSc in Genomics and Experimental Biology from the University of Lausanne, Switzerland. Mr. Magistretti also holds a CAIA designation (Chartered Alternative Investment Analyst).
He graduated from Ecole Polytechnique Fédérale de Lausanne (EPFL, Switzerland) in the Management of Biotech, Medtech and Pharma Ventures.